Bevacizumab for the management of low-grade serous ovarian cancer in first-line and recurrent disease

被引：0
|
作者：
Van Den Kieboom, Natalia [1 ]
Ottenbourgs, Tine [2 ]
Van Nieuwenhuysen, Els [3 ,4 ]
机构：
[1] Katholieke Univ Leuven, Leuven Canc Inst, Dept Gynaecol & Obstet, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven Canc Inst, Lab Gynaecol Oncol, Leuven, Belgium
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Luxembourg Gynaecol Oncol Grp BGOG, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EV338/#101
引用
收藏
页码：A258 / A259
页数：2
相关论文
共 50 条
  • [31] SELUMETINIB HAS ACTIVITY IN LOW-GRADE SEROUS OVARIAN CANCER
    不详
    CANCER DISCOVERY, 2013, 3 (02) : 134 - 134
  • [32] Low-grade serous Ovarian Cancer - Fertility Preservation or Hysterectomy?
    Geretto, Magdalena
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : 491 - 491
  • [33] Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
    Onoprienko, Arina
    Bartl, Thomas
    Grimm, Christoph
    Concin, Nicole
    Polterauer, Stephan
    CANCERS, 2024, 16 (19)
  • [34] Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer
    Lambrechts, Sandrina
    Smeets, Dominiek
    Moisse, Matthieu
    Braicu, Elena Ioana
    Vanderstichele, Adriaan
    Zhao, Hui
    Van Nieuwenhuysen, Els
    Berns, Els
    Sehouli, Jalid
    Zeillinger, Robert
    Darb-Esfahani, Silvia
    Castillo-Tong, Dan Cacsire
    Lambrechts, Diether
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 51 - 64
  • [35] Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma
    McIntyre, John B.
    Rambau, Peter F.
    Chan, Angela
    Yap, Sidney
    Morris, Don
    Nelson, Gregg S.
    Kobel, Martin
    HISTOPATHOLOGY, 2017, 70 (03) : 347 - 358
  • [36] Recurrence of low-grade serous ovarian cancer successfully treated with Gemcitabine and Bevacizumab: a case report and literature review
    Sato, Hanako
    Kotani, Yasushi
    Miyagawa, Chiho
    Yahata, Tamaki
    Murakami, Kosuke
    Nakai, Hidekatsu
    Otani, Tomoyuki
    Matsumura, Noriomi
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (05) : 107 - 111
  • [37] Management of low-grade serous ovarian neoplasm in the setting of fertility preservation
    Marchocki, Zibi
    Rouzbahman, Marjan
    Chawla, Tanya
    May, Taymaa
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1834 - 1839
  • [38] First-line bevacizumab for ovarian cancer—new standard of care?
    Susana Banerjee
    Stan B. Kaye
    Nature Reviews Clinical Oncology, 2012, 9 : 194 - 196
  • [39] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [40] Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Grisham, Rachel N.
    Sala, Evis
    Zhou, Qin
    Iasonos, Alexia
    DeLair, Deborah
    Iyer, Gopa
    Hyman, David Michael
    Spriggs, David R.
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345